Compounded Tirzepatide Online. 2026 Provider Comparison
Compare verified compounded tirzepatide online offers and published billing terms. Review the exact medication and commitment before enrolling.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Compare the options first
Full comparison & price terms ↓A short preview in editorial order—not a guarantee of the cheapest total bill. Read the commitment terms before choosing.
$49/mo
Lower listed rate · not necessarily monthly billing
Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
From $249/mo
Lower listed rate · not necessarily monthly billing
At the August 26, 2026 price check, Direct Meds listed sublingual semaglutide from $249/month and injections from $297/month. Its public process page says medication, nurse support, shipping, and digital follow-ups are included. A licensed clinician reviews the online intake; confirm treatment, dose, and checkout terms before purchase. Provider-wide published rate; confirm the exact treatment quote.
From $159/mo
Lower listed rate · not necessarily monthly billing
At the October 21, 2026 check, Shed listed compounded semaglutide from $159/month and compounded tirzepatide as low as $239/month, and states that pricing does not increase with dose. Health coaching, follow-ups and shipping are included. Provider-wide published rate; confirm the exact treatment quote.
Compounded tirzepatide offers a lower-cost alternative to brand-name Zepbound and Mounjaro. It is available via licensed compounding pharmacies in injectable, oral-dissolving, and sublingual formulations.
Compounded tirzepatide contains the same active ingredient as Zepbound and Mounjaro but is custom-mixed by a compounding pharmacy.
Adults seeking dual GIP/GLP-1 receptor agonist therapy who prefer compounded pricing and dose customization.
Pricing typically ranges from $200 to $400 per month depending on dose and frequency.
Verified Offers for compounded
WellMedr
Compounded GLP-1 care with semaglutide shown at $49/mo or tirzepatide at $89/mo with 12-month prepayment; $99/$129 month to month. Verified affiliate coverage is weight loss only.
Direct Meds
Compounded GLP-1 clinic with transparent pricing and dedicated nurse support.
Shed Rx
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Women-focused telehealth combining compounded GLP-1 weight loss with HRT support.
Flexible, medically guided compounded GLP-1 weight loss with transparent monthly pricing.
Refills
Multi-category telehealth platform covering GLP-1, ED, hair loss, and longevity peptides with no membership fees and flat dosage pricing.
Found
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
Sprout Health
Compounded GLP-1 plus NAD+ therapy with transparent flat-rate pricing and fast shipping.
Premium GLP-1 clinic with a needle-free sublingual semaglutide tablet option.
Enhance.MD
Provider-led metabolic and NAD+ wellness platform with transparent flat pricing.
Cielo Health
Mission-driven compounded GLP-1 clinic with same-day intake review, transparent pricing, and 10% of proceeds donated to charity.
Telos Rx
Peptide-led integrated telehealth covering GLP-1 weight loss, anti-aging, and sexual wellness under one care team — oral tirzepatide from $49/mo, injectable from $139/mo, with flat pricing and no dose surcharges.
Flat-rate compounded GLP-1 clinic — semaglutide from $99/mo and tirzepatide from $125/mo at every dose, with a 6-month money-back guarantee.
Remote Pharmacy
No-subscription compounded GLP-1 and men's health clinic with same-day approvals, free shipping, and unlimited physician messaging.
Bodybuilding Health+
Provider-guided metabolic, cellular, and sexual performance protocols designed for people who train.
AltRx
Budget-first compounded GLP-1 clinic with a low advertised entry price ($89/mo semaglutide), transparent pricing, and optional brand-name GLP-1 access.
Pallas Health
Online GLP-1 and NAD+ care with bundled provider support, a $139 compounded-semaglutide first month, and a dedicated NAD+ program.
Compounded GLP-1 telehealth focused on flat plan pricing, with advertised rates tied to annual prepayment.
2026 Price Comparison. Verified Medication Offers
Published provider price terms for offers with a supplied affiliate destination specifically mapped to this medication. Medication, clinician, shipping, and plan-length terms vary; confirm the final checkout total before enrolling.
Recorded price-check dates: 15 June 2026 – 21 October 2026. Per-provider dates below; these are not a guarantee of today's checkout price.
Rates use different billing terms and are not necessarily all-in or month-to-month. Confirm total charges and cancellation terms. Compounded medications are not FDA-approved finished drugs; pharmacy type alone does not establish legality or clinical suitability.
18 providers · Trustpilot scores are customer opinions, not treatment results.
| Provider & billing terms | Lower listed rate | Higher listed rate | Pharmacy | Reviews & price check | Actions |
|---|---|---|---|---|---|
| WellMedrBest Value Rate Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. | Lower listed rate$49/mo | Higher listed rate$99 – $129/mo | Pharmacy503A | 4.6/5 1,963 reviews 30 August 2026 | Go WellMedrRead full review |
| Direct Meds At the August 26, 2026 price check, Direct Meds listed sublingual semaglutide from $249/month and injections from $297/month. Its public process page says medication, nurse support, shipping, and digital follow-ups are included. A licensed clinician reviews the online intake; confirm treatment, dose, and checkout terms before purchase. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $249/mo | Higher listed rateUp to $297/mo | PharmacyBrand Rx | 4.6/5 14,599 reviews 26 August 2026 | Go Direct MedsRead full review |
| Shed Rx At the October 21, 2026 check, Shed listed compounded semaglutide from $159/month and compounded tirzepatide as low as $239/month, and states that pricing does not increase with dose. Health coaching, follow-ups and shipping are included. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $159/mo | Higher listed rateUp to $239/mo | PharmacyBrand Rx | 4.7/5 956 reviews 21 October 2026 | Go Shed RxRead full review |
| Gala Health Combined GLP-1 + HRT plans bundle medication and provider oversight in a single monthly price. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $149/mo | Higher listed rateUp to $399/mo | PharmacyNot disclosed | 4.6/5 3,986 reviews 15 June 2026 | Go Gala HealthRead full review |
| Embody Transparent monthly pricing that bundles compounded GLP-1 medication, provider oversight, and shipping into a single fee. No separate membership charge, no dose surcharges, and no long-term contracts. Pricing is disclosed upfront before you complete intake. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $149/mo | Higher listed rateUp to $349/mo | PharmacyBrand Rx | 3.8/5 6,332 reviews 15 June 2026 | Go EmbodyRead full review |
| Refills Refills advertises GLP-1 programs from $5/day (approximately $150/mo). No membership or app fees. All dosages are priced the same (no dose-tier price increases). Free shipping. ED medications (sildenafil, tadalafil, Cialis, Viagra), hair loss (finasteride, minoxidil), and longevity peptides (NAD+, sermorelin, methylene blue) are also available. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $150/mo | Higher listed rateUp to $299/mo | PharmacyNot disclosed | 4.0/5 1,425 reviews 24 June 2026 | Go RefillsRead full review |
| Found At the October 21, 2026 check, Found's CORE plan was $129 every 30 days, or $594 for six months (about $99/month); the PLUS self-pay plan was $199/month. Found's terms state GLP-1 medications are not included in any plan fee; Found works with your insurer on coverage, otherwise medication is paid separately. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $129/mo | Higher listed rateUp to $349/mo | PharmacyBrand Rx | 4.0/5 729 reviews 21 October 2026 | Go FoundRead full review |
| Sprout Health Flat-rate pricing covers the medication and provider visits in one number. Combined GLP-1 + NAD+ stacks are priced as bundles. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $99/mo | Higher listed rateUp to $299/mo | PharmacyNot disclosed | 4.0/5 158 reviews 15 June 2026 | Go Sprout HealthRead full review |
| Willow Willow bundles physician oversight, medication, free two-day shipping, and unlimited messaging into one premium monthly fee. There is no brand-name medication option and no insurance billing. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $299/mo | Higher listed rateUp to $549/mo | PharmacyBrand Rx | 3.9/5 359 reviews 15 June 2026 | Go WillowRead full review |
| Enhance.MD Enhance.MD uses transparent flat pricing, the monthly subscription includes provider oversight and the chosen medication. NAD+ wafers and injectables are listed at flat in-cart prices. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $149/mo | Higher listed rateUp to $399/mo | PharmacyNot disclosed | 4.1/5 159 reviews 15 June 2026 | Go Enhance.MDRead full review |
| Cielo Health Cielo charges from $115/mo for compounded semaglutide and from $180/mo for compounded tirzepatide on a 3-month plan. Single-month rates are $199/mo (semaglutide) and $299/mo (tirzepatide). Physician consult and shipping are included at no extra cost. Every batch is third-party tested. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $115/mo | Higher listed rateUp to $299/mo | PharmacyNot disclosed | 4.3/5 10 reviews 24 June 2026 | Go Cielo HealthRead full review |
| Telos Rx Oral tirzepatide from $49/mo; injectable tirzepatide from $139/mo; semaglutide from $99/mo. Price varies by treatment and plan length. | Lower listed rate$49/mo | Higher listed rateUp to $399/mo | Pharmacy503A/503B | 4.9/5 3 reviews 13 July 2026 | Go Telos RxRead full review |
| TrimiLowest Flat Rate Flat rate at every dose. | Lower listed rate$99/mo | Higher listed rate$125/mo | Pharmacy503A | Score unavailable 24 June 2026 | Go TrimiRead full review |
| Remote Pharmacy Remote Pharmacy charges no subscription or membership fee. Compounded tirzepatide starts at $229/mo (starter dose) and $349/mo (maintenance). Compounded semaglutide pricing is comparable. Physician consult and shipping are included at no extra charge. Same-day approvals available for orders placed before 2 pm ET. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $229/mo | Higher listed rateUp to $349/mo | PharmacyNot disclosed | Score unavailable 24 June 2026 | Go Remote PharmacyRead full review |
| Bodybuilding Health+ Bundled monthly pricing covers medication and provider oversight. Performance-stack add-ons are billed per protocol. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $96/mo | Higher listed rateUp to $299/mo | PharmacyNot disclosed | Score unavailable 15 June 2026 | Go Bodybuilding Health+Read full review |
| AltRx AltRx advertises compounded semaglutide from $89/mo (promotional first-month pricing) with standard pricing from $159/mo. Compounded tirzepatide (GLP-1+GIP) starts at $129/mo promotional or $279/mo standard. Brand-name Zepbound and Mounjaro are available from $1,249/mo. No hidden fees, no insurance required. Buy Now Pay Later options available. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $89/mo | Higher listed rateUp to $279/mo | PharmacyBrand Rx | Score unavailable 24 June 2026 | Go AltRxRead full review |
| Pallas Health Pallas advertises compounded semaglutide at $139 for the first month, then $597 every 12 weeks ($199/mo average), and compounded tirzepatide at $179 for the first month, then $897 every 12 weeks ($299/mo average). Prices include provider care; confirm the renewal charge and medication selection during intake. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $139/mo | Higher listed rateUp to $299/mo | PharmacyBrand Rx | Score unavailable 15 August 2026 | Go Pallas HealthRead full review |
| CoreAge Rx CoreAge Rx’s landing page lists $99/mo and $149/mo GLP-1 plan figures and states that displayed starting prices are based on a 12-month plan paid in full. Confirm the medication, total prepaid amount, fulfillment, and cancellation terms during enrollment; month-to-month pricing was not published on the reviewed page. Provider-wide published rate; confirm the exact treatment quote. | Lower listed rateFrom $99/mo | Higher listed rateUp to $149/mo | PharmacyNot disclosed | Score unavailable 15 August 2026 | Go CoreAge RxRead full review |
Provider links may earn a commission. Rate sorting compares the displayed numbers, not equivalent treatment plans or total commitments. How we check price terms →
The Regulatory Landscape for Compounded Tirzepatide in 2026
Tirzepatide was removed from the FDA drug shortage list in October 2024, and the legal grace period for compounding under the shortage exemption ended in early 2025. This is a materially different situation from compounded semaglutide, where the 503B debate is still contested. For tirzepatide, the FDA's position is clearer: mass-market compounded tirzepatide for weight loss is not permitted. The only remaining legal pathway is the FDCA 503A personalisation exception: patient-specific compounding where the prescriber documents a clinical need that cannot be met by the brand-name product.
In practice, legitimate personalisation-exception cases include: documented allergy to an inactive ingredient in Zepbound, a required dose strength not available commercially, or a specific formulation need (e.g., a patient who cannot self-inject and needs a different delivery format). These are genuine edge cases, not a loophole for general-use compounding. If a telehealth platform is offering compounded tirzepatide to the general public without a documented personalisation rationale, it is operating outside FDA guidance.
The market has responded accordingly: most major telehealth platforms (FuturHealth, TrimRx, TMates, SkinnyRx) have phased out compounded tirzepatide for weight loss and shifted to brand-name Zepbound via LillyDirect vials. The economics now largely support this shift. LillyDirect vials at $349–$549/month are competitive with what compounded tirzepatide cost in 2023–2024.
Compounded Tirzepatide vs. Zepbound LillyDirect Vials: The Real Comparison
The economic case for compounded tirzepatide has largely collapsed since LillyDirect vials launched. At $349/month for the 5 mg dose and $549/month for 7.5 mg and above, LillyDirect vials are within $50–$150/month of what most compounding pharmacies charged in 2024, and that gap is often closed by the telehealth platform's consult fee on top of the compounded price. For a patient paying $250/month for compounded tirzepatide plus a $50/month platform fee, switching to LillyDirect vials at $349/month is essentially cost-neutral.
The quality argument is unambiguous: Zepbound is manufactured by Eli Lilly under FDA-approved GMP conditions with documented potency, sterility, and shelf-life testing. Compounding pharmacies vary widely in quality control, the FDA has issued warning letters to multiple compounders for sterility failures and potency deviations. For a medication that requires precise dosing to achieve the SURMOUNT trial results, manufacturing consistency matters.
The remaining case for compounded tirzepatide is narrow: patients with a documented personalisation need (allergy to Zepbound excipients, non-standard dose requirement) and patients on a specific split-dose protocol that cannot be replicated with the available Zepbound pen strengths. Outside these cases, brand-name Zepbound via LillyDirect is the stronger choice in 2026.
What the Studies Actually Show
Compounded tirzepatide contains the same active ingredient as Zepbound and Mounjaro. There are no randomized trials of compounded formulations themselves; efficacy is inferred from the trials of the underlying API and from the FDA prescribing information for the brand-name product.
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
| GI side effects (FDA prescribing information)4 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥5%, constipation ≥5% |
| Boxed warning4 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| A1C reduction (T2D, SURPASS program)5 | ≈1.9–2.4% A1C reduction at 15 mg weekly across SURPASS-1 through SURPASS-5 |
| Compounded tirzepatide — evidence basis6 | Active ingredient is identical to Zepbound/Mounjaro; efficacy is inferred from the active ingredient. FDA does not formally approve compounded products |
Frequently Asked Questions
Is compounded tirzepatide still legal in 2026?
The FDA removed tirzepatide from the drug shortage list in October 2024 and the legal grace period for compounding ended in early 2025. Compounded tirzepatide for weight loss is now restricted to the FDCA 503A personalisation exception. i.e., patient-specific clinical need that cannot be met by the brand-name product (allergies to inactive ingredients, dose customization beyond available strengths). Most platforms that previously sold mass-marketed compounded tirzepatide have either pivoted to brand-name Zepbound or shifted to other peptides. Any platform still mass-marketing compounded tirzepatide as a generic alternative is operating outside FDA guidance.
How much does compounded tirzepatide cost?
Where legitimately available under the personalisation exception, $200–$400/mo. Compare to LillyDirect Zepbound vials at $349–$549/mo, the price gap has narrowed dramatically since 2024. For most patients there's now no economic case for compounded over LillyDirect vials.
Is compounded tirzepatide as effective as Zepbound?
The active ingredient is the same. The variable is formulation quality, compounding pharmacies vary widely in API sourcing, sterile compounding standards, and quality control. There are no head-to-head RCTs of compounded vs brand-name tirzepatide. We recommend brand-name Zepbound (or LillyDirect vials) for any patient who has insurance coverage or can afford the $349–$549/mo cash-pay price.
Which platforms still offer compounded tirzepatide?
As of mid-2026, most major telehealth platforms have phased out compounded tirzepatide for weight loss. A handful (TMates, JRNYS) still offer it under the personalisation exception for documented clinical need. Most have shifted their formulary to brand-name Zepbound (often via LillyDirect vials) and to compounded peptides outside the GLP-1 class.
What about compounded tirzepatide with B12 or other adjuncts?
Adding B12 or other ingredients to tirzepatide does not exempt it from the post-shortage compounding restrictions. The FDA has issued specific guidance that adjunct ingredients are not a legitimate basis for compounding under the personalisation exception. Platforms marketing 'tirzepatide + B12' as a workaround are operating in a gray zone.
Should I switch from compounded tirzepatide to Zepbound?
For most patients, yes. LillyDirect vials at $349–$549/mo offer FDA-approved manufacturing, supply reliability, and similar economics. Standard practice is to maintain the current dose and re-prescribe as Zepbound. Patients on customized doses (e.g., split-dose protocols, non-standard strengths) may have legitimate clinical reasons to remain on compounded under the 503A exception.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.